Quantcast

Latest Herceptin Stories

2014-04-10 12:26:46

Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and...

2014-04-03 12:30:00

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth SummaryGBI Research has released the pharma report "Monoclonal...

2014-02-20 08:32:05

SEATTLE, WA and BOULDER, CO, Feb. 20, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array....

2014-02-03 08:27:37

SEATTLE AND BOULDER, CO, Feb. 3, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with...

2013-12-12 10:59:30

98.7 percent are cancer free for at least 3 years A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found. The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer...

2013-12-10 23:20:12

Reportbuyer.com just published a new market research report: Biosimilar Opportunities in an Evolving Market. London (PRWEB) December 10, 2013 Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two...

2013-10-29 23:22:36

Reportbuyer.com just published a new market research report: World Biological Drugs Market 2013-2023. London (PRWEB) October 29, 2013 Report Details Biologics - discover and assess products with highest revenue potential Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects. In that...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related